By Marie Rosenthal, MS
The World Health Organization updated its global HIV treatment recommendations based on new data showing that even though dolutegravir (DTG) during conception increased the occurrence of neural tube defect (NTD), the risk was not much higher than that of other antiretrovirals (ARVs). The announcement was made during IAS 2019, the International AIDs Society annual meeting, in Mexico City.
For the past year, the safety of DTG during pregnancy has been one of the most urgent